About the Panel:
Mr. Avi Meizler founded (1990) and was the President until June, 2012 of Meizler UCB Biopharma S.A. Mr. Meizler is Co-founded and CEO Advantech Bioscience Pharmaceutical Ltd, being responsible for the development of 02 biological components. Investor and Director of the board of Therapix Bioscience Ltd, Orimune Bio, Kadimastem Stem Cellss, Raziel Therapeutics, Nirolin lifescience. He has been an experienced businessman and entrepreneur in Brazil since 1979 in the fields of pharmaceuticals, engineering and construction.
Mr. Ronen Hausirer is a partner in the technology licensing group within the High-tech department at HFN. Specializing in commercial transactions between Israeli companies and major corporations in Asia, Europe and the U.S., Ronen advises clients from a range of industries including medical device, pharmaceuticals and bio-tech companies in a variety of transactions. Ronen specializes in technology licensing, technology transfer, general commercial transactions, joint ventures and strategic collaborations.
Albert Einstein Hospital in Brazil is the first Bone Marrow Transplantation Center in Latin America to receive FACT accreditation. HIAE is accredited for antilogous and allergenic transplantation. The hospital was founded in 1971 with the mission of providing quality health care, generating knowledge, and promoting social responsibility. In recent decades, an expansion plan doubled the hospital’s service area, expanded social programs of assistance to needy communities, and turned the hospital into a benchmark in organ transplants, in the public sector. HIAE works in close partnerships with governments for health assistance in various regions of São Paulo metropolis. The hospital’s research and educational institute has already trained approximately 130,000 professionals and conducts hundreds of studies annually.